What Aligos Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Blatt Lawrence | Chief Executive Officer | Oct 25 | Grant / award · A | +610,277 | $0.76 | +$462K | 1,847,575 |
| Nuechterlein Carole | Director | Oct 25 | Open-market buy · P | +7,933,601 | $0.76 | +$6M | 11,025,941 |
| Scopa James Paul | Director | Oct 25 | Grant / award · A | +183,083 | $0.76 | +$139K | 183,083 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | +2,226 | — | — | 4,452 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | −8,383 | — | — | 0 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | +8,383 | — | — | 8,383 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | −9,719 | — | — | 0 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | +9,719 | — | — | 9,719 |
| Woiwode Thomas | Director | Jun 11 | Other Transaction · J | −485,979 | — | — | 1,457,937 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | +2,226 | — | — | 2,226 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | −8,385 | — | — | 0 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | +8,385 | — | — | 8,385 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | −9,720 | — | — | 0 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | +9,720 | — | — | 9,720 |
| Woiwode Thomas | Director | Apr 26 | Other Transaction · J | −485,979 | — | — | 1,943,916 |
| Woiwode Thomas | Director | Oct 20 | Open-market buy · P | +200,000 | $15.00 | +$3M | 862,444 |
| Woiwode Thomas | Director | Oct 20 | Derivative Conversion · C | +198,485 | — | — | 662,444 |
| Woiwode Thomas | Director | Oct 20 | Derivative Conversion · C | +463,959 | — | — | 463,959 |
| Woiwode Thomas | Director | Oct 20 | Derivative Conversion · C | +85,065 | — | — | 2,429,895 |
| Woiwode Thomas | Director | Oct 20 | Derivative Conversion · C | +198,839 | — | — | 2,344,830 |
Loading...
